highest dose of glp-1 ​"Triple-Hormone" Drug Shows Record Weight Loss: At the American Diabetes Association's 2026 Scientific Sessions, researchers unveiled phase 3 trial results for retatrutide, the first therapy to GLP-1 Oral Solution – Affordable

Retatrutide is an investigational triple agonist peptide developed to activate three key receptor systems involved in metabolic regulation: GLP-1 receptor GIP receptor glucagon receptor This receptor profile makes Retatrutide mechanistically broader than Semaglutide and Tirzepatide

A: Never stop or change a prescription medication without talking to your prescriber

If you are at week 12 and have not hit the 5% threshold, that is the signal to reassess

Tirzepatide microdosing Tirzepatide targets both GLP-1 and GIP receptors

Its taken as a pill, and it improves the bodys response to insulin and decreases glucose production in the liver